FI4249515T3 - Humanisoituja tai kimeerisiä CD3-vasta-aineita - Google Patents

Humanisoituja tai kimeerisiä CD3-vasta-aineita

Info

Publication number
FI4249515T3
FI4249515T3 FIEP23174159.6T FI23174159T FI4249515T3 FI 4249515 T3 FI4249515 T3 FI 4249515T3 FI 23174159 T FI23174159 T FI 23174159T FI 4249515 T3 FI4249515 T3 FI 4249515T3
Authority
FI
Finland
Prior art keywords
heavy chain
seq
set forth
sequence
amino acid
Prior art date
Application number
FIEP23174159.6T
Other languages
English (en)
Finnish (fi)
Inventor
Edward Norbert Van Den Brink
Joost J Neijssen
Aran Frank Labrijn
Joyce Meesters
Janine Schuurman
Isil Altintas
Paul Parren
Rik Rademaker
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2014/050340 external-priority patent/WO2014108483A1/en
Application filed by Genmab As filed Critical Genmab As
Application granted granted Critical
Publication of FI4249515T3 publication Critical patent/FI4249515T3/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FIEP23174159.6T 2014-01-09 2015-01-08 Humanisoituja tai kimeerisiä CD3-vasta-aineita FI4249515T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2014/050340 WO2014108483A1 (en) 2013-01-10 2014-01-09 Inert format
DKPA201400009 2014-01-09
PCT/EP2014/064326 WO2015001085A1 (en) 2013-07-05 2014-07-04 Humanized or chimeric cd3 antibodies

Publications (1)

Publication Number Publication Date
FI4249515T3 true FI4249515T3 (fi) 2025-09-02

Family

ID=52143134

Family Applications (2)

Application Number Title Priority Date Filing Date
FIEP23174159.6T FI4249515T3 (fi) 2014-01-09 2015-01-08 Humanisoituja tai kimeerisiä CD3-vasta-aineita
FIC20250036C FIC20250036I1 (fi) 2014-01-09 2025-12-09 Epkoritamabi

Family Applications After (1)

Application Number Title Priority Date Filing Date
FIC20250036C FIC20250036I1 (fi) 2014-01-09 2025-12-09 Epkoritamabi

Country Status (31)

Country Link
US (5) US10465006B2 (cg-RX-API-DMAC7.html)
EP (5) EP3016681B1 (cg-RX-API-DMAC7.html)
JP (7) JP6546162B2 (cg-RX-API-DMAC7.html)
KR (4) KR20250078622A (cg-RX-API-DMAC7.html)
CN (5) CN105722529B (cg-RX-API-DMAC7.html)
AU (4) AU2014286116A1 (cg-RX-API-DMAC7.html)
BR (1) BR122023002590B1 (cg-RX-API-DMAC7.html)
CA (1) CA2915575A1 (cg-RX-API-DMAC7.html)
CY (1) CY1122840T1 (cg-RX-API-DMAC7.html)
DK (2) DK3016681T5 (cg-RX-API-DMAC7.html)
EA (1) EA201690167A1 (cg-RX-API-DMAC7.html)
ES (2) ES2776706T3 (cg-RX-API-DMAC7.html)
FI (2) FI4249515T3 (cg-RX-API-DMAC7.html)
HK (1) HK1231369A1 (cg-RX-API-DMAC7.html)
HR (2) HRP20200382T1 (cg-RX-API-DMAC7.html)
HU (2) HUE048722T2 (cg-RX-API-DMAC7.html)
IL (4) IL311371B2 (cg-RX-API-DMAC7.html)
LT (2) LT3016681T (cg-RX-API-DMAC7.html)
ME (1) ME03675B (cg-RX-API-DMAC7.html)
MX (2) MX373245B (cg-RX-API-DMAC7.html)
NL (1) NL301352I2 (cg-RX-API-DMAC7.html)
NZ (1) NZ715896A (cg-RX-API-DMAC7.html)
PL (1) PL3016681T3 (cg-RX-API-DMAC7.html)
PT (2) PT3016681T (cg-RX-API-DMAC7.html)
RS (2) RS60131B1 (cg-RX-API-DMAC7.html)
SG (2) SG11201510739TA (cg-RX-API-DMAC7.html)
SI (2) SI3016681T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202000287T1 (cg-RX-API-DMAC7.html)
UA (1) UA119646C2 (cg-RX-API-DMAC7.html)
WO (2) WO2015001085A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201800385B (cg-RX-API-DMAC7.html)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201815863T4 (tr) 2010-11-30 2018-11-21 Chugai Pharmaceutical Co Ltd Sitotoksisiteyi indükleyen terapötik madde.
AU2013285355A1 (en) 2012-07-06 2015-01-29 Genmab B.V. Dimeric protein with triple mutations
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
IL311371B2 (en) 2013-07-05 2024-09-01 Genmab As CD3 antibodies of human origin or chimeras
EP4067383A1 (en) 2013-07-25 2022-10-05 Cytomx Therapeutics Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
TWI701042B (zh) * 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
KR102568808B1 (ko) * 2014-04-07 2023-08-18 추가이 세이야쿠 가부시키가이샤 면역활성화 항원 결합 분자
AU2015260230A1 (en) 2014-05-13 2016-11-17 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
AU2015292406B2 (en) 2014-07-25 2021-03-11 Cytomx Therapeutics, Inc Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same
LT3699198T (lt) 2014-11-17 2025-05-12 Regeneron Pharmaceuticals, Inc. Būdai navikams gydyti naudojant cd3×cd20 bispecifinį antikūną
LT3221357T (lt) 2014-11-20 2020-08-25 F. Hoffmann-La Roche Ag Bendros lengvosios grandinės ir naudojimo būdai
MX2017006571A (es) 2014-11-20 2017-09-29 Hoffmann La Roche Moleculas de union a antigeno biespecificas activadoras de celulas t.
JP6853176B2 (ja) 2015-01-08 2021-03-31 ゲンマブ エー／エス Ｃｄ３およびｃｄ２０に対する二重特異性抗体
EP3277725B1 (en) 2015-03-30 2020-11-25 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
BR112018000696A2 (pt) * 2015-07-15 2018-09-18 Genmab As ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit?
US11702477B2 (en) 2015-11-06 2023-07-18 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
WO2017086367A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
CN105296421B (zh) * 2015-11-24 2019-01-29 高岱清 一种双特异性抗体活化的t细胞及制备方法与应用
ES2901794T3 (es) 2015-12-09 2022-03-23 Hoffmann La Roche Anticuerpo anti-CD20 de tipo II para reducir la formación de anticuerpos antifármaco
CA3013554A1 (en) 2016-02-05 2017-08-10 Orionis Biosciences Nv Targeted therapeutic agents and uses thereof
RS64266B1 (sr) 2016-03-22 2023-07-31 Hoffmann La Roche Bispecifični molekul koji aktivira t ćeliju koji se aktivira proteazom
EP3433280B1 (en) * 2016-03-22 2023-04-19 F. Hoffmann-La Roche AG Protease-activated t cell bispecific molecules
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
AU2018276419A1 (en) 2016-06-02 2019-10-17 F. Hoffmann-La Roche Ag Type II anti-CD20 antibody and anti-CD20/CD3 bispecific antibody for treatment of cancer
CN116903741A (zh) 2016-06-20 2023-10-20 科马布有限公司 特异性结合于pd-l1的抗体或其抗原结合片段及其用途
MA45672A (fr) * 2016-07-14 2019-05-22 Biontech Ag Anticorps multispécifiques dirigés contre cd40 et cd137
CN110087530A (zh) 2016-12-07 2019-08-02 普罗根尼蒂公司 胃肠道检测方法、装置和系统
US10906985B2 (en) 2017-02-06 2021-02-02 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
LT3592769T (lt) 2017-03-09 2024-08-26 Genmab A/S Antikūnai, atpažįstantys pd-l1
EP4108183A1 (en) 2017-03-30 2022-12-28 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
IL270366B1 (en) * 2017-05-08 2025-09-01 Adimab Llc Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
AU2018290228B2 (en) 2017-06-21 2021-07-01 Gilead Sciences, Inc. Multispecific antibodies that target HIV gp120 and CD3
EP3668898B1 (en) 2017-08-14 2023-07-05 MorphoSys AG Humanized antibodies for cd3
US20190100587A1 (en) * 2017-10-02 2019-04-04 Covagen Ag IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
BR112020007309A2 (pt) 2017-10-14 2020-09-29 Cytomx Therapeutics, Inc. anticorpos, anticorpos ativáveis, anticorpos biespecíficos e anticorpos ativáveis biespecíficos e métodos de uso dos mesmos
KR101973060B1 (ko) * 2017-10-20 2019-04-26 주식회사 녹십자 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물
CN107860925B (zh) * 2017-11-03 2019-07-12 合肥瀚科迈博生物技术有限公司 用于检测血清中HuA21抗体的ELISA检测试剂盒
CN109971725B (zh) * 2017-12-28 2024-02-02 上海细胞治疗研究院 抗体修饰的嵌合抗原受体修饰t细胞及其用途
EP3752196A4 (en) * 2018-02-15 2022-03-23 MacroGenics, Inc. CD3-BINDING DOMAIN VARIANTS AND THEIR USE IN COMBINATION THERAPIES FOR THE TREATMENT OF DISEASES
CR20250348A (es) 2018-03-12 2025-09-23 Genmab As ANTICUERPOS QUE SE UNEN A 5T4 (Divisional 2020-463)
CA3093330A1 (en) * 2018-03-14 2019-09-19 Novimmune Sa Anti-cd3 epsilon antibodies and methods of use thereof
TWI793325B (zh) * 2018-05-23 2023-02-21 美商輝瑞大藥廠 對cd3具特異性之抗體及其用途
EP3802608B1 (en) * 2018-05-24 2025-04-30 Janssen Biotech, Inc. Anti-cd3 antibodies and uses thereof
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
FI3844189T3 (fi) 2018-08-31 2025-03-05 Regeneron Pharma Annostusstrategia, joka lieventää bispesifisten CD3/CD20-vasta-aineiden sytokiinien vapautumisoireyhtymää
WO2020076970A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. B7h3 single domain antibodies and therapeutic compositions thereof
CA3114693A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. 5t4 single domain antibodies and therapeutic compositions thereof
CN113166263A (zh) 2018-10-11 2021-07-23 印希比股份有限公司 Dll3单域抗体及其治疗性组合物
JP7453219B2 (ja) 2018-10-11 2024-03-19 インヒブリックス， インコーポレイテッド Ｐｄ－１単一ドメイン抗体およびその治療用組成物
CN116726362A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CN113396161A (zh) * 2018-12-04 2021-09-14 诺华股份有限公司 针对cd3的结合分子及其用途
KR102878895B1 (ko) 2019-05-21 2025-10-31 노파르티스 아게 Cd19 결합 분자 및 이의 용도
EP4028424A1 (en) 2019-09-12 2022-07-20 Genmab A/S Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer
EP4039707A4 (en) * 2019-09-30 2022-11-16 Harbour Biomed (Shanghai) Co., Ltd Cd3-targeting antibody, bispecific antibody and use thereof
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
JP2023507846A (ja) 2019-12-23 2023-02-27 デナリ セラピューティクス インコーポレイテッド プログラニュリン変異体
US20230057263A1 (en) * 2020-01-06 2023-02-23 Cytomx Therapeutics, Inc. Single-and multi-chain polypeptides that bind specifically to cd3 epsilon
KR20220148175A (ko) 2020-01-29 2022-11-04 인히브릭스, 인크. Ｃｄ28 단일 도메인 항체 및 이의 다가 및 다중특이적 구조체
WO2021167952A2 (en) * 2020-02-20 2021-08-26 The Feinstein Institutes For Medical Research Agonist antibodies against endoglin and uses thereof
CN115298221A (zh) 2020-03-18 2022-11-04 健玛保 结合b7h4的抗体
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
CN115916166A (zh) 2020-05-08 2023-04-04 健玛保 针对cd3和cd20的双特异性抗体
CN116249714A (zh) 2020-05-27 2023-06-09 詹森生物科技公司 包含cd3抗原结合结构域的蛋白质及其用途
BR112023003366A2 (pt) 2020-08-25 2023-05-09 Gilead Sciences Inc Moléculas multiespecíficas de ligação ao antígeno que têm como alvo hiv e métodos de uso
CN116472060A (zh) 2020-09-02 2023-07-21 健玛保 抗体疗法
CN116782933A (zh) 2020-09-10 2023-09-19 健玛保 用于治疗弥漫性大b细胞淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体
BR112023004351A2 (pt) * 2020-09-10 2023-04-04 Genmab As Método para tratar linfoma folicular em um sujeito humano
CA3190349A1 (en) 2020-09-10 2022-03-17 Brian Elliott Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
JP2023542092A (ja) 2020-09-10 2023-10-05 ジェンマブ エー／エス びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
CA3192251A1 (en) 2020-09-10 2022-03-17 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
CN116406293A (zh) 2020-09-10 2023-07-07 健玛保 用于治疗滤泡性淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体
IL301513A (en) 2020-10-02 2023-05-01 Genmab As Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3
KR102671734B1 (ko) * 2021-04-13 2024-06-04 건국대학교 글로컬산학협력단 개과 동물의 CD3ε 특이적 항체 또는 그의 항원 결합 단편
AU2021443318A1 (en) 2021-04-30 2023-09-07 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
WO2022228706A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
MX2023012351A (es) 2021-05-07 2023-10-31 Genmab As Composiciones farmaceuticas que comprenden anticuerpos biespecificos que se unen al inhibidor de la activacion de celulas t que contiene un dominio v-set 1 (b7h4) y cumulo de diferenciacion 3 (cd3).
CN115558023A (zh) * 2021-07-02 2023-01-03 安源医药科技（上海）有限公司 抗cd3抗体及其用途
IL311805A (en) 2021-10-08 2024-05-01 Genmab As Antibodies that bind to CD30 and CD3
WO2023144290A1 (en) 2022-01-28 2023-08-03 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
JP2025503177A (ja) 2022-01-28 2025-01-30 ジェンマブ エー／エス びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
KR20240164782A (ko) 2022-03-23 2024-11-20 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이적 항체와 화학요법의 병용 치료
WO2023198839A2 (en) 2022-04-13 2023-10-19 Genmab A/S Bispecific antibodies against cd3 and cd20
CA3255366A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Pharmaceutical compositions based on bispecific anti-CD20/anti-CD3 antibodies and methods of use
CN119212716A (zh) * 2022-05-09 2024-12-27 杭州微诺迈博生物科技有限公司 包含多特异性抗体的治疗剂及其在肿瘤治疗中的应用
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
EP4612179A1 (en) 2022-11-02 2025-09-10 Genmab A/S Bispecific antibodies against cd3 and cd20 for treating richter's syndrome
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
TW202506178A (zh) 2023-04-05 2025-02-16 丹麥商珍美寶股份有限公司 包含與ｃｄ３０和ｃｄ３結合之抗體之醫藥組成物
KR20250169618A (ko) 2023-04-13 2025-12-03 젠맵 에이/에스 Cd3 및 cd20에 대한 이중특이적 항체를 사용하여 림프종을 치료하는 방법
WO2025057225A1 (en) * 2023-09-14 2025-03-20 Invitrogen Bioservices India Private Limited Engineered antibodies and uses thereof
EP4590715A1 (en) 2023-09-21 2025-07-30 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2025061993A1 (en) 2023-09-21 2025-03-27 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2025116732A1 (en) * 2023-12-01 2025-06-05 Rijksuniversiteit Groningen Methods and kits for detecting proliferating cells
WO2025199352A2 (en) 2024-03-20 2025-09-25 Juno Therapeutics, Inc. Antibodies specific for solute carrier family 34 member 2 (slc34a2)
WO2025240670A2 (en) 2024-05-15 2025-11-20 Abalytics Oncology, Inc. Anti-pd-1 antibodies and related binding molecules and methods and uses thereof

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
IL144084A0 (en) 1999-02-03 2002-05-23 Biosante Pharmaceuticals Inc Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
PT1523496E (pt) 2002-07-18 2011-09-29 Merus B V Produção de misturas de anticorpos de forma recombinante
PT1558648E (pt) 2002-10-17 2012-04-23 Genmab As Anticorpos monoclonais humanos contra cd20
JP4633788B2 (ja) 2004-04-13 2011-02-16 エフ．ホフマン−ラ ロシュ アーゲー 抗ｐ−セレクチン抗体
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
DK1844074T3 (da) 2005-02-03 2013-07-15 Antitope Ltd Humane antistoffer og proteiner
EP2395026B1 (en) 2005-02-08 2018-01-24 The Chemo-Sero-Therapeutic Research Institute Method for improving antibody
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
RU2515108C2 (ru) 2005-08-19 2014-05-10 Эббви Инк Иммуноглобулин с двойными вариабельными доменами и его применения
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007042261A2 (en) * 2005-10-11 2007-04-19 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
EA016609B1 (ru) 2005-11-28 2012-06-29 Генмаб А/С Рекомбинантные моновалентные антитела и способы их получения
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
EP1999154B1 (en) 2006-03-24 2012-10-24 Merck Patent GmbH Engineered heterodimeric protein domains
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
PL2155788T3 (pl) * 2007-04-03 2013-02-28 Amgen Res Munich Gmbh Swoiste międzygatunkowe bispecyficzne czynniki wiążące
SG182234A1 (en) 2007-04-03 2012-07-30 Amgen Res Munich Gmbh Cross-species-specific cd3-epsilonbinding domain
AU2008265984B2 (en) 2007-06-21 2014-07-17 Macrogenics, Inc. Covalent diabodies and uses thereof
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
DE102008039957A1 (de) 2008-08-27 2010-03-04 Continental Automotive Gmbh Verfahren zur Ermittlung eines Unfallschwerekriteriums mittels eines Beschleunigungssignals und eines Körperschallsignals
JP5397668B2 (ja) 2008-09-02 2014-01-22 ソニー株式会社 記憶素子および記憶装置
FR2935974B1 (fr) 2008-09-15 2010-10-08 Centre Nat Rech Scient Derives de metalloporphyrines, nanoparticules les comprenant
CA2738568C (en) * 2008-10-01 2024-02-20 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
MX2011006416A (es) 2008-12-19 2011-07-12 Macrogenics Inc Diacuerpos covalentes y sus usos.
CA2759233C (en) 2009-04-27 2019-07-16 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
KR101791430B1 (ko) 2009-11-30 2017-10-30 얀센 바이오테크 인코포레이티드 이펙터 기능이 제거된 항체 Ｆｃ 돌연변이체
US8786135B2 (en) 2010-03-25 2014-07-22 Mitsubishi Electric Research Laboratories, Inc. Wireless energy transfer with anisotropic metamaterials
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
TWI653333B (zh) * 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
CA2796181C (en) 2010-04-20 2023-01-03 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
JP6022444B2 (ja) 2010-05-14 2016-11-09 ライナット ニューロサイエンス コーポレイション ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法
CN107253992B (zh) 2010-05-27 2022-03-11 根马布股份公司 针对her2的单克隆抗体
EP2593475B1 (en) 2010-07-14 2016-03-02 Merck Sharp & Dohme Corp. Anti-addl monoclonal antibody and uses thereof
TW201208703A (en) * 2010-08-17 2012-03-01 Roche Glycart Ag Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
MX340556B (es) 2010-08-24 2016-07-14 Roche Glycart Ag Anticuerpos biespecificos activables.
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
TR201815863T4 (tr) * 2010-11-30 2018-11-21 Chugai Pharmaceutical Co Ltd Sitotoksisiteyi indükleyen terapötik madde.
BR112013021473A2 (pt) * 2011-02-23 2020-08-04 F. Hoffmann-La Roche Ag anticorpos contra il33r humano e seus usos
CN103796677B (zh) * 2011-04-20 2019-08-16 健玛保 针对her2和cd3的双特异性抗体
CN107722124A (zh) 2011-05-21 2018-02-23 宏观基因有限公司 能够与人和非人cd3结合的cd3结合分子
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
WO2013060867A2 (en) 2011-10-27 2013-05-02 Genmab A/S Production of heterodimeric proteins
WO2013112945A1 (en) 2012-01-27 2013-08-01 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
AU2013285355A1 (en) * 2012-07-06 2015-01-29 Genmab B.V. Dimeric protein with triple mutations
IL311371B2 (en) 2013-07-05 2024-09-01 Genmab As CD3 antibodies of human origin or chimeras
JP2016531100A (ja) * 2013-07-12 2016-10-06 ザイムワークス，インコーポレイテッド 二重特異的なｃｄ３及びｃｄ１９抗原結合構築物
CN106029696B (zh) * 2013-12-17 2020-07-28 基因泰克公司 抗cd3抗体及使用方法
JP6853176B2 (ja) * 2015-01-08 2021-03-31 ゲンマブ エー／エス Ｃｄ３およびｃｄ２０に対する二重特異性抗体
BR112018000696A2 (pt) 2015-07-15 2018-09-18 Genmab As ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit?
CH713600A2 (de) 2017-03-21 2018-09-28 Digi Sens Ag Vorrichtung und Verfahren zum Messen einer Last.
EP3668898B1 (en) * 2017-08-14 2023-07-05 MorphoSys AG Humanized antibodies for cd3
CA3192251A1 (en) * 2020-09-10 2022-03-17 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
CA3190349A1 (en) * 2020-09-10 2022-03-17 Brian Elliott Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
CN116406293A (zh) * 2020-09-10 2023-07-07 健玛保 用于治疗滤泡性淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体
CN116782933A (zh) * 2020-09-10 2023-09-19 健玛保 用于治疗弥漫性大b细胞淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体

Also Published As

Publication number Publication date
CA2915575A1 (en) 2015-01-08
LT3016681T (lt) 2020-03-25
EA201690167A1 (ru) 2016-06-30
EP4631978A2 (en) 2025-10-15
NL301352I2 (nl) 2025-12-16
MX2020004503A (es) 2020-08-13
EP3091998B1 (en) 2025-08-20
WO2015104346A1 (en) 2015-07-16
US20230374131A1 (en) 2023-11-23
RS60131B1 (sr) 2020-05-29
JP6619342B2 (ja) 2019-12-11
US10465006B2 (en) 2019-11-05
IL311371B2 (en) 2024-09-01
KR20250078622A (ko) 2025-06-02
IL290613B2 (en) 2024-11-01
JP7757247B2 (ja) 2025-10-21
SG11201510739TA (en) 2016-01-28
ZA201800385B (en) 2019-09-25
AU2025256200A1 (en) 2025-11-13
BR112015032986A2 (pt) 2017-08-22
CN113248615A (zh) 2021-08-13
KR20220025210A (ko) 2022-03-03
IL276530B (en) 2022-03-01
MX2015017487A (es) 2016-03-21
EP4249515A2 (en) 2023-09-27
KR102813816B1 (ko) 2025-05-29
EP3091998A1 (en) 2016-11-16
NZ715896A (en) 2022-02-25
AU2022203851B2 (en) 2025-07-24
SMT202500322T1 (it) 2025-11-10
DK3016681T3 (da) 2020-03-09
US20160168247A1 (en) 2016-06-16
MX373245B (es) 2020-05-11
US20200123255A1 (en) 2020-04-23
HUE072527T2 (hu) 2025-11-28
SI3016681T1 (sl) 2020-04-30
ES3038421T3 (en) 2025-10-13
EP3016681A1 (en) 2016-05-11
DK3016681T5 (da) 2020-05-04
US11613575B2 (en) 2023-03-28
PT4249515T (pt) 2025-09-08
IL311371A (en) 2024-04-01
US10407501B2 (en) 2019-09-10
EP4631978A3 (en) 2025-12-24
JP2020048564A (ja) 2020-04-02
JP7104000B2 (ja) 2022-07-20
HRP20200382T1 (hr) 2020-06-12
CN105722529B (zh) 2021-06-08
CN106255507B (zh) 2025-05-02
JP2022163009A (ja) 2022-10-25
JP7389833B2 (ja) 2023-11-30
JP6546162B2 (ja) 2019-07-17
SI4249515T1 (sl) 2025-11-28
US20160333095A1 (en) 2016-11-17
EP4249515B1 (en) 2025-06-18
UA119646C2 (uk) 2019-07-25
PL3016681T3 (pl) 2020-06-15
JP2016529882A (ja) 2016-09-29
CY1122840T1 (el) 2021-05-05
AU2014286116A1 (en) 2016-02-04
KR102531517B1 (ko) 2023-05-12
KR20160027177A (ko) 2016-03-09
EP3693385A1 (en) 2020-08-12
SMT202000287T1 (it) 2020-07-08
AU2020202792B2 (en) 2022-06-23
EP4249515A3 (en) 2023-11-15
EP3016681B1 (en) 2019-12-18
AU2020202792A1 (en) 2020-05-21
IL276530A (en) 2020-09-30
US20200199229A1 (en) 2020-06-25
CN106255507A (zh) 2016-12-21
HRP20251127T1 (hr) 2025-11-21
JP7208129B2 (ja) 2023-01-18
ES2776706T3 (es) 2020-07-31
SG10201800982QA (en) 2018-03-28
IL290613B1 (en) 2024-07-01
JP2024026114A (ja) 2024-02-28
ME03675B (me) 2020-10-20
DK4249515T3 (en) 2025-09-15
IL243127B (en) 2020-08-31
IL311371B1 (en) 2024-05-01
JP2020005635A (ja) 2020-01-16
CN120365424A (zh) 2025-07-25
FIC20250036I1 (fi) 2025-12-09
AU2020202792B9 (en) 2022-07-07
IL290613A (en) 2022-04-01
KR20230073341A (ko) 2023-05-25
WO2015001085A1 (en) 2015-01-08
HK1231369A1 (zh) 2017-12-22
KR102363220B1 (ko) 2022-02-15
AU2022203851A1 (en) 2022-06-23
CN105722529A (zh) 2016-06-29
RS67220B1 (sr) 2025-10-31
CN113248615B (zh) 2025-07-04
JP2017505121A (ja) 2017-02-16
JP2022101539A (ja) 2022-07-06
LT4249515T (lt) 2025-08-25
BR122023002590B1 (pt) 2023-12-05
HUE048722T2 (hu) 2020-08-28
PT3016681T (pt) 2020-03-26
CN118063621A (zh) 2024-05-24

Similar Documents

Publication Publication Date Title
FI4249515T3 (fi) Humanisoituja tai kimeerisiä CD3-vasta-aineita
IL318350A (en) Bispecific antibodies against cd3 and cd20
MY186351A (en) Multispecific antibodies
HRP20191462T1 (hr) Antitijela usmjerena protiv her-3 i njihove uporabe
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
CY1120414T1 (el) Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους
RU2018102606A (ru) Молекулы, связывающиеся с psl pseudomonas, и пути их применения
HRP20200390T1 (hr) Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
MY200988A (en) CD3 Binding Antibodies
HRP20240719T1 (hr) Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba
RU2016100892A (ru) Антитела против tweakr и их применение
HRP20210113T1 (hr) Stabilizirani topljivi prefuzijski rsv f protein za upotrebu u profilaksi rsv infekcije
EP4524161A3 (en) Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
PH12018502204A1 (en) Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
PE20190737A1 (es) Anticuerpos anti-cd27
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
MX347829B (es) Molécula fv de unión a antígeno multivalente.
MA39266A (fr) Anticorps bispécifiques anti cd3epsilon et bcma
ME02678B (me) Antitijela na ox-40 i postupci njihove primjene
AR065506A1 (es) Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades
MX2016004928A (es) Secuencias de anticuerpos con reaccion cruzada para staphylococcus aureus.
PH12017500699A1 (en) Antibodies that bind to ccr6 and their uses
JP2017511152A5 (cg-RX-API-DMAC7.html)
RU2016141285A (ru) Биспецифические антигенсвязывающие полипептиды